论文部分内容阅读
目的:探讨腹腔镜联合促性腺激素释放激素激动剂治疗子宫内膜异位症临床疗效及应用价值。方法:将宁波市北仑区人民医院治疗的子宫内膜异位症患者108例,采用随机数字法分为观察组和对照组,对照组给予腹腔镜治疗,观察组联合促性腺激素释放激素激动剂治疗,记录两组治疗情况。结果:观察组治疗总有效率94.44%,显著高于对照组的75.93%,差异有统计学意义。观察组治疗后VAS评分(1.32±0.26)分,Kupperman评分(8.35±1.54)分;对照组治疗后VAS评分(2.41±1.06)分,Kupperman评分(12.82±2.79)分,组间对比差异有统计学意义。观察组治疗后卵泡刺激素(1.75±0.38)U/L,黄体生成素(2.16±0.49)U/L,雌二醇(92.34±6.12)pmol/L;对照组治疗后卵泡刺激素(2.56±1.01)U/L,黄体生成素(3.44±1.18)U/L,雌二醇(146.83±11.16)pmol/L,组间对比差异有统计学意义。结论:联合促性腺激素释放激素激动剂治疗子宫内膜异位症可以提升腹腔镜治疗效果,降低子宫内膜厚度与盆腔肿物大小,临床疗效可靠。
Objective: To investigate the clinical efficacy and clinical value of laparoscopic combined with gonadotropin-releasing hormone agonist in the treatment of endometriosis. Methods: 108 patients with endometriosis treated by Beilun District People’s Hospital of Ningbo were randomly divided into observation group and control group. The control group was treated with laparoscopy. The observation group was treated with gonadotropin-releasing hormone agonist Treatment, record the two groups of treatment. Results: The total effective rate of the observation group was 94.44%, which was significantly higher than that of the control group (75.93%), the difference was statistically significant. VAS score (1.32 ± 0.26) and Kupperman score (8.35 ± 1.54) in the observation group after treatment; VAS score (2.41 ± 1.06) and Kupperman score (12.82 ± 2.79) in the control group after treatment, statistical differences between groups were statistically Significance of learning. In the control group, follicle stimulating hormone (1.75 ± 0.38) U / L, luteinizing hormone (2.16 ± 0.49) U / L and estradiol (92.34 ± 6.12) pmol / 1.01) U / L, luteinizing hormone (3.44 ± 1.18) U / L and estradiol (146.83 ± 11.16) pmol / L respectively. There was significant difference between the two groups. Conclusion: The combination of gonadotropin-releasing hormone agonist in treatment of endometriosis can improve the effect of laparoscopy and reduce the thickness of endometrium and pelvic tumor, and the clinical effect is reliable.